medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (3)

Nosocomial infections in pediatric patients with hematological diseases, 2006-2009

Martell-Martorell L, Arencibia-Núñez A

Language: Spanish
References: 36
Page: 253-262
PDF size: 315.83 Kb.


ABSTRACT

A cross-sectional study was performed at the Pediatric Department of the Institute of Hematology and Immunology from December 2006 to March 2009. There were 36 patients who had 60 infections with microbiological documentation, which represented 29 % of the total. Most infections occurred in patients with hematological malignancies, of which a large portion had severe neutropenia. In infectious episodes Gram-negative bacteria was the most frequent, followed by Gram positive and fungi, this latter was always associated with bacterial infections. Coagulase negative staphylococcus was the organism with the highest incidence. Patients who had central venous catheter placed in the femoral region had a higher risk of negative bacilli bacteremia.


REFERENCES

  1. Steuber CP. General considerations of neoplastic diseases. En: McMillan JA, editor. Oski's Pediatrics: Principles & Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins Publishers; 2006.

  2. Pizzo PA. The compromised host. En: Goldman L, Bennett JC, editors. Cecil textbook of medicine. 21st ed. Philadelphia: WB Saunders; 2000. p. 1569-81.

  3. Díaz C, Salavert M, Aguado JM, Jarque I, Lizasoain M, Sanz MA. Evaluación individualizada del riesgo de infecciones en el paciente oncohematológico. Rev Esp Quimioterap. 2006;19(2):117-29.

  4. Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341(22):893-900.

  5. Vusirikala M. Supportive care in hematologic malignancies. En: Greer JP, Lukens JN, editors. Wintrobe's Clinical Hematology. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.

  6. Mermel LA, Farr BM, Sherertz RJ, Raad I, O'Grady N, Harris JS, et al. Guidelines for the management of intravascular catheterrelated infections. Clin Infect Dis. 2001;32(16):1249-72.

  7. Carreras E, Mensa J. Neutropenia febril: pasado, presente y futuro. Enferm Infecc Microbiol Clin. 2005;23(5):2-6.

  8. Mateos MC, Arguiñano JM, Ardaiz MA. Infecciones en pacientes oncohematológicos no trasplantados. An Sist Sanit Navar. 2005;28(1):59-81.

  9. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(1):32-7.

  10. Arnello ML, Quintana JA, Barraza P. Neutropenia febril en niños con cáncer en un centro asistencial en Santiago, Chile. Rev Chil Infect. 2007;24(1):27-32.

  11. Butt T, Afzal RK, Ahmad RN, Salman M, Mahmood A, Anwar M. Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern. J Ayub Med Coll Abbottabad. 2004 16(1):18-22.

  12. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A Prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296-304.

  13. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2009;31(9):623-9.

  14. El-Mahallawya H, Sidhoma I, El-Dinb A, Zamzama M, El-Lamieb MM. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: a one-year study. Int J Infect Dis. 2005;9(1):43-51.

  15. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis. 2002;34(6):730-51.

  16. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(1):32-7.

  17. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958-66.

  18. Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000;18(21):3699-706.

  19. Viscoli C, Castagnola E, Giacchino M, Cesaro S, Properzi E, Tucci F, et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Eur J Cancer. 1999;35(5):770-4.

  20. Jumaa PA, Neringer R. Frequency of isolation of pathogens from nosocomial bloodstream infection in a tertiary referral hospital in the United Arab Emirates. Int J Infect Dis. 2006;10(3):264-5.

  21. Teira R, Lazarralde E, Santamaría JM, Zubero Z, Muñoz P, Baraiaetxaburu J, et al. Incidencia de bacteriemia en grupos histológicos de neoplasias hematológicas. Enferm Infecc Microbiol Clin. 2003;21:24-9.

  22. Urrea M, Rives S, Cruz O, Navarro A, García JJ, Estella J. Nosocomial infections among pediatric hematology/oncology patients: results of a prospective incidence study. Am J Infect Control. 2004 32(4):205-8.

  23. Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12(3):217-23.

  24. Reilly AF, Lange BJ. Infections with Viridans Group Streptococci in Children with Cancer. Pediatr Blood Cancer. 2007;49(6):774-80.

  25. Hartel C, Deuster M, Lehrnbecher T, Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49(6):767-73.

  26. Jugo J, Kennedy R, Crowe MJ, Lamrock G, McClurg RB, Rooney PJ, et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect. [Original article]. 2002;50(1):48-56.

  27. Cherif H, Kronvall G, Björkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J. 2003;4(6):420-6.

  28. Yébenes JC, Capdevila JA. Infección relacionada con catéteres intravasculares. Med Clin (Barc). 2002;119(13):500-7.

  29. Vázquez JG, García M, Fortanelli R, Huerta G, Solórzano F, Miranda MG. Frecuencia de microorganismos aislados en pacientes pediátricos con neutropenia y fiebre que cuentan con dispositivos vasculares y su evolución clínica. Enf Inf Microbiol. 2006;26(3):66-71.

  30. Santolaya ME, Álvarez AM, Avilés CL, Becker A, Cofré J, Cumsille MA, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol. 2004;22(18):3784-9.

  31. Poele EM, Tissing WJ, Kamps WA, de Bont ES. Risk assessment in fever and neutropenia in children with cancer: What did we learn? Crit Rev Oncol Hematol. 2009;72(1):45-55.

  32. Chiou PF, Chang C, Wen YK, Yang Y. Antibiotic lock technique reduces the incidence of temporary catheter related infections. Clin Nephrol. 2006;65:419-22.

  33. RS D. Removing the golden coat of Staphylococcus aureus. N Engl J Med. 2010;359:85-7.

  34. Cermak P, Kolar M, Látal T. Frequency of Gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. Int J Antimicrob Agents. 2004;23(4):401-4.

  35. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med. 2010;362:1804-13.

  36. De Pauw BE. Treatment of documented and suspected neutropenia-associated invasive fungal infections. J Chemother. 2001 13(1):181-92.




2020     |     www.medigraphic.com